---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-071430"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-13T23:34:38.690463+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports Phase 2 CF data: ELX-02 shows +2.83% ppFEV1 in 6 responders, supports pivotal trial

## Summary
- 13 evaluable patients; 6 responders had +2.83% mean ppFEV1 increase at Day 35 vs Day 1.
- Overall ppFEV1 change was -0.31% at Day 35; disease progression pre-treatment averaged -4.26%/yr.
- Safety follow-up at 28 days showed -2.69% ppFEV1 decline; no treatment-related serious adverse events.
- Results bolster decision to advance ELX-02 into pivotal Alport syndrome trial.
- Interim topline from 11 patients reported Sep 2022; final analysis confirms activity.

## SEC filing metadata
- accession: 0001104659-23-071430
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923071430/0001104659-23-071430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923071430/tm2318799d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-071430
- JSON: https://secwatch.observer/filing/0001104659-23-071430.json
- Plain text: https://secwatch.observer/filing/0001104659-23-071430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.